Glenmark Pharmaceuticals Receives Tentative ANDA Approval for Clindamycin Phosphate Foam, 1%

/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN[1] Foam, 1%, of Mylan Pharmaceuticals Inc.

(Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )
[1]All brand names and trademarks are the property of their respective owners
[2]Market includes brand and all available therapeutic equivalents
*IQVIA[TM] National Sales Perspectives: Retail & Non-Retail, April 2019
About Glenmark Pharmaceuticals